As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Entera Bio Ltd. The largest reported stake is Biotechnology Value Fund L P's, at 9.99%. 7 filings are on record since November 14, 2025 (Schedule 13D, August 4, 2026).
Sell to companies like Entera Bio Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Venrock Healthcare Capital Partners III, L.P. · Sole voting: 0 · Shared voting: 8,861,763 · Sole dispositive: 0 · Shared dispositive: 8,861,763 · SCHEDULE 13G, 2026-10-30
- · Reporting person: Biotechnology Value Fund L P · Sole voting: 0 · Shared voting: 9,171,741 · Sole dispositive: 0 · Shared dispositive: 9,171,741 · SCHEDULE 13D, 2026-08-04
- · Reporting person: TCG Crossover GP III, LLC · Sole voting: 0 · Shared voting: 12,254,901 · Sole dispositive: 0 · Shared dispositive: 12,254,901 · SCHEDULE 13G, 2026-08-04
- · Reporting person: Vivo Opportunity Fund Holdings, L.P. · Sole voting: 4,330,882 · Shared voting: 0 · Sole dispositive: 4,330,882 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-04
- · Holder: Seven Fleet Capital Management LP · Percent: 4.1% · SCHEDULE 13G
Entera Bio Ltd. has 7 Schedule 13D or 13G filings on record since 2025-11-14. 4 holders' latest filing reports 5% or more of ordinary shares, par value of nis 0.0000769. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Biotechnology Value Fund L P | 9.99% | 9,171,741 | SCHEDULE 13D, 2026-08-04 | 2026-07-28 |
| TCG Crossover GP III, LLC | 7.1% | 12,254,901 | SCHEDULE 13G, 2026-08-04 | 2026-07-28 |
| Vivo Opportunity, LLC | 6.9% | 11,817,401 | SCHEDULE 13G, 2026-08-04 | 2026-07-28 |
| Venrock Healthcare Capital Partners III, L.P. | 5.1% | 8,861,763 | SCHEDULE 13G, 2026-10-30 | 2026-10-23 |
| Longitude Capital Partners V, LLC | 4.6% | 7,843,138 | SCHEDULE 13G, 2026-08-04 | 2026-07-28 |
| Seven Fleet Capital Management LP | 4.1% | 7,053,898 | SCHEDULE 13G, 2026-08-04 | 2026-07-28 |
| Point72 Asset Management, L.P. | 2.6% | 1,183,116 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
Holding shares or following this stake? See who's behind Entera Bio Ltd. and the warning signs.
Free to see. No signup.
Keep reading
More on Entera Bio Ltd. and the records around it.
Entera Bio Ltd. elsewhere on the record
- Company profile and every filing Aug 2026
- Form D filing Aug 2026
- Leadership changes Jul 2026
- Who owns it
Companies that share a holder
- Longitude Capital Partners V, LLC also filed stake reports on 3 other companies: CytomX Therapeutics, Inc. (May 2026), Mobia Medical, Inc. (May 2026), Veradermics, Incorporated (May 2026)
- Seven Fleet Horizon Master Fund LP also filed stake reports on 3 other companies: CytomX Therapeutics, Inc. (May 2026), Veradermics, Inc (May 2026), CG Oncology, Inc. (Oct 2025)
- TCG Crossover GP III, LLC also filed stake reports on 3 other companies: Research Alliance Corporation III (Aug 2026), Editas Medicine, Inc. (Jun 2026), InflaRx N.V. (May 2026)
Watch Entera Bio Ltd.
Get an email when Entera Bio Ltd. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Entera Bio Ltd.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Entera Bio Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Entera Bio Ltd. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Biotechnology Value Fund L P | 0 | 9,171,741 | 0 | 9,171,741 | SCHEDULE 13D, 2026-08-04 |
| Bvf I Gp LLC | 0 | 9,171,741 | 0 | 9,171,741 | SCHEDULE 13D, 2026-08-04 |
| Biotechnology Value Fund Ii LP | 0 | 6,685,480 | 0 | 6,685,480 | SCHEDULE 13D, 2026-08-04 |
| Bvf Ii Gp LLC | 0 | 6,685,480 | 0 | 6,685,480 | SCHEDULE 13D, 2026-08-04 |
| Biotechnology Value Trading Fund OS LP | 0 | 1,124,329 | 0 | 1,124,329 | SCHEDULE 13D, 2026-08-04 |
| BVF Partners OS Ltd. | 0 | 1,124,329 | 0 | 1,124,329 | SCHEDULE 13D, 2026-08-04 |
| Bvf Gp Holdings LLC | 0 | 15,857,221 | 0 | 15,857,221 | SCHEDULE 13D, 2026-08-04 |
| Bvf Partners L P | 0 | 17,225,121 | 0 | 17,225,121 | SCHEDULE 13D, 2026-08-04 |
| Bvf Inc | 0 | 17,225,121 | 0 | 17,225,121 | SCHEDULE 13D, 2026-08-04 |
| Lampert Mark N | 0 | 17,225,121 | 0 | 17,225,121 | SCHEDULE 13D, 2026-08-04 |
| TCG Crossover GP III, LLC | 0 | 12,254,901 | 0 | 12,254,901 | SCHEDULE 13G, 2026-08-04 |
| TCG Crossover Fund III, L.P. | 0 | 12,254,901 | 0 | 12,254,901 | SCHEDULE 13G, 2026-08-04 |
| Chen Yu | 0 | 12,254,901 | 0 | 12,254,901 | SCHEDULE 13G, 2026-08-04 |
| Vivo Opportunity Fund Holdings, L.P. | 4,330,882 | 0 | 4,330,882 | 0 | SCHEDULE 13G, 2026-08-04 |
| Vivo Opportunity Co-Invest, L.P. | 2,718,137 | 0 | 2,718,137 | 0 | SCHEDULE 13G, 2026-08-04 |
| Vivo Opportunity Co-Invest (Cycle 3), L.P. | 4,768,382 | 0 | 4,768,382 | 0 | SCHEDULE 13G, 2026-08-04 |
| Vivo Opportunity, LLC | 11,817,401 | 0 | 11,817,401 | 0 | SCHEDULE 13G, 2026-08-04 |
| Vivo Opportunity Cayman Fund, L.P. | 437,500 | 0 | 437,500 | 0 | SCHEDULE 13G, 2026-08-04 |
| Vivo Opportunity Cayman, LLC | 437,500 | 0 | 437,500 | 0 | SCHEDULE 13G, 2026-08-04 |
| Venrock Healthcare Capital Partners III, L.P. | 0 | 8,861,763 | 0 | 8,861,763 | SCHEDULE 13G, 2026-10-30 |
| VHCP Co-Investment Holdings III, LLC | 0 | 8,861,763 | 0 | 8,861,763 | SCHEDULE 13G, 2026-10-30 |
| Venrock Healthcare Capital Partners EG, L.P. | 0 | 8,861,763 | 0 | 8,861,763 | SCHEDULE 13G, 2026-10-30 |
| VHCP Management III, LLC | 0 | 8,861,763 | 0 | 8,861,763 | SCHEDULE 13G, 2026-10-30 |
| VHCP Management EG, LLC | 0 | 8,861,763 | 0 | 8,861,763 | SCHEDULE 13G, 2026-10-30 |
The latest filing identifies Entera Bio Ltd. by CUSIP M40527109 and gives its principal executive office as Kiryat Hadassah, Minrav Building, Fifth Floor, Jerusalem (SCHEDULE 13G, 2026-10-30).
What the percentages are based on
Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentage of ordinary shares of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.Venrock Healthcare Capital Partners III, L.P., SCHEDULE 13G, 2026-10-30
Purpose of Transaction (Item 4)
Biotechnology Value Fund L P
The Reporting Persons purchased the securities reported owned herein based on the Reporting Persons' belief that such securities, when purchased, were undervalued and represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of Shares at prices that would make the purchase or sale of Shares desirable, the Reporting Persons may endeavor to increase or decrease their position in the Issuer through, among other things, the purchase or sale of Shares on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Persons may deem advisable. April Securities Purchase Agreement and Registration Rights Agreement On April 1, 2026, the Issuer entered into a Securities Purchase Agreement (the "April Securities Purchase Agreement") with certain of the Reporting Persons providing for the private placement (the "April Private Placement") to the applicable Reporting Persons of an aggregate of 7,827,789 units (collectively, the "Units"), each Unit consisting of (i) one Share (or, in lieu thereof, one pre-funded warrant to purchase one Share (the "April Pre-Funded Warrants")) and (ii) one warrant to purchase one and a half Shares (the "Warrants"), for aggregate proceeds of approximately $10.0 million (or $1.2775 per Unit). The closing of the April Private Placement occurred on April 2, 2026 (the "April Closing Date"). On …The first part of Item 4 of the SCHEDULE 13D filed 2026-08-04; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-11-14 | Point72 Asset Management, L.P. | 2.6% | SCHEDULE 13G/A |
| 2026-08-04 | Biotechnology Value Fund L P | 9.99% | SCHEDULE 13D |
| 2026-08-04 | Seven Fleet Capital Management LP | 4.1% | SCHEDULE 13G |
| 2026-08-04 | TCG Crossover GP III, LLC | 7.1% | SCHEDULE 13G |
| 2026-08-04 | Longitude Capital Partners V, LLC | 4.6% | SCHEDULE 13G |
| 2026-08-04 | Vivo Opportunity, LLC | 6.9% | SCHEDULE 13G |
| 2026-10-30 | Venrock Healthcare Capital Partners III, L.P. | 5.1% | SCHEDULE 13G |
Questions about who owns Entera Bio Ltd.
Who owns Entera Bio Ltd.?
On this page, 4 holders' latest ownership filings report 5% or more of Entera Bio Ltd.: Biotechnology Value Fund L P (9.99%, Schedule 13D, filed 2026-08-04), TCG Crossover GP III, LLC (7.1%, Schedule 13G, filed 2026-08-04), Vivo Opportunity, LLC (6.9%, Schedule 13G, filed 2026-08-04) and Venrock Healthcare Capital Partners III, L.P. (5.1%, Schedule 13G, filed 2026-10-30).
Who are the largest shareholders of Entera Bio Ltd.?
By the share each holder's latest filing reports, the largest holders of Entera Bio Ltd. on this page are Biotechnology Value Fund L P (9.99%), TCG Crossover GP III, LLC (7.1%) and Vivo Opportunity, LLC (6.9%).
When did Biotechnology Value Fund L P buy into Entera Bio Ltd.?
The filings give report dates, not purchase dates. The earliest filing from Biotechnology Value Fund L P on this page is the Schedule 13D, filed 2026-08-04, reporting 9.99%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Entera Bio Ltd.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 27, 2026 | Leadership change: Haya Taitel departs, Director | — | Leadership changes | Source |
| October 6, 2026 | Leadership change: Laura Hamill appointed, Director, and 1 more | — | Leadership changes | Source |
| August 12, 2026 | Form D, private offering | $275M sold | Form D page | Source |
| July 28, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Entera Bio Ltd.: every filing and event
Tools for this story
Each opens in a new tab, filled in for Entera Bio Ltd.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.